Selumetinib for the treatment of cancer

Kristen Keon Ciombor, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: The MAPK pathway is essential for regulation of cellular proliferation, differentiation and survival. Multiple human cancers have demonstrated activation of Raf-mitogen-Activated kinase kinase (MEK)-extracellular signal-related kinase signaling, a hallmark of these tumors. Efforts to inhibit various protein kinases in this pathway have led to the development of MEK inhibitors. Selumetinib is one such drug, functioning as an oral, selective non-ATP-competitive MEK1/2 inhibitor.

Areas covered: In this article, the authors discuss the underlying biology of MEK inhibition and its rationale in cancer treatment. Furthermore, the authors summarize the clinical development of selumetinib in various tumor types, from initial Phase I studies to randomized Phase II studies, both as monotherapy or in combination with other chemotherapeutics.

Expert opinion: Given the frequency of activated MAPK signaling in multiple tumor types, the potent MEK inhibitor selumetinib had strong preclinical and early clinical rationale, particularly in those tumors harboring KRAS or BRAF mutations. While efficacy signals have been seen in various tumor types treated with selumetinib, better biomarkers are needed to select patients most likely to respond favorably to this agent. Furthermore, combinatorial therapy with selumetinib and other targeted agents can likely be optimized to maximize the antitumor effect of inhibiting RAS/MAPK signaling.

Original languageEnglish (US)
Pages (from-to)111-123
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Phosphotransferases
Mitogens
Neoplasms
Therapeutics
AZD 6244
Expert Testimony
Protein Kinases
Biomarkers
Cell Proliferation
Mutation
Survival
Pharmaceutical Preparations

Keywords

  • ARRY-142886
  • AZD6244
  • Extracellular signal-related kinase
  • MAPK
  • Mitogen-Activated protein kinase
  • Selumetinib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Selumetinib for the treatment of cancer. / Ciombor, Kristen Keon; Bekaii-Saab, Tanios.

In: Expert Opinion on Investigational Drugs, Vol. 24, No. 1, 01.01.2015, p. 111-123.

Research output: Contribution to journalArticle

Ciombor, Kristen Keon ; Bekaii-Saab, Tanios. / Selumetinib for the treatment of cancer. In: Expert Opinion on Investigational Drugs. 2015 ; Vol. 24, No. 1. pp. 111-123.
@article{b6dedab06d97479f914b78d74ef84ae0,
title = "Selumetinib for the treatment of cancer",
abstract = "Introduction: The MAPK pathway is essential for regulation of cellular proliferation, differentiation and survival. Multiple human cancers have demonstrated activation of Raf-mitogen-Activated kinase kinase (MEK)-extracellular signal-related kinase signaling, a hallmark of these tumors. Efforts to inhibit various protein kinases in this pathway have led to the development of MEK inhibitors. Selumetinib is one such drug, functioning as an oral, selective non-ATP-competitive MEK1/2 inhibitor.Areas covered: In this article, the authors discuss the underlying biology of MEK inhibition and its rationale in cancer treatment. Furthermore, the authors summarize the clinical development of selumetinib in various tumor types, from initial Phase I studies to randomized Phase II studies, both as monotherapy or in combination with other chemotherapeutics.Expert opinion: Given the frequency of activated MAPK signaling in multiple tumor types, the potent MEK inhibitor selumetinib had strong preclinical and early clinical rationale, particularly in those tumors harboring KRAS or BRAF mutations. While efficacy signals have been seen in various tumor types treated with selumetinib, better biomarkers are needed to select patients most likely to respond favorably to this agent. Furthermore, combinatorial therapy with selumetinib and other targeted agents can likely be optimized to maximize the antitumor effect of inhibiting RAS/MAPK signaling.",
keywords = "ARRY-142886, AZD6244, Extracellular signal-related kinase, MAPK, Mitogen-Activated protein kinase, Selumetinib",
author = "Ciombor, {Kristen Keon} and Tanios Bekaii-Saab",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/13543784.2015.982275",
language = "English (US)",
volume = "24",
pages = "111--123",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Selumetinib for the treatment of cancer

AU - Ciombor, Kristen Keon

AU - Bekaii-Saab, Tanios

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: The MAPK pathway is essential for regulation of cellular proliferation, differentiation and survival. Multiple human cancers have demonstrated activation of Raf-mitogen-Activated kinase kinase (MEK)-extracellular signal-related kinase signaling, a hallmark of these tumors. Efforts to inhibit various protein kinases in this pathway have led to the development of MEK inhibitors. Selumetinib is one such drug, functioning as an oral, selective non-ATP-competitive MEK1/2 inhibitor.Areas covered: In this article, the authors discuss the underlying biology of MEK inhibition and its rationale in cancer treatment. Furthermore, the authors summarize the clinical development of selumetinib in various tumor types, from initial Phase I studies to randomized Phase II studies, both as monotherapy or in combination with other chemotherapeutics.Expert opinion: Given the frequency of activated MAPK signaling in multiple tumor types, the potent MEK inhibitor selumetinib had strong preclinical and early clinical rationale, particularly in those tumors harboring KRAS or BRAF mutations. While efficacy signals have been seen in various tumor types treated with selumetinib, better biomarkers are needed to select patients most likely to respond favorably to this agent. Furthermore, combinatorial therapy with selumetinib and other targeted agents can likely be optimized to maximize the antitumor effect of inhibiting RAS/MAPK signaling.

AB - Introduction: The MAPK pathway is essential for regulation of cellular proliferation, differentiation and survival. Multiple human cancers have demonstrated activation of Raf-mitogen-Activated kinase kinase (MEK)-extracellular signal-related kinase signaling, a hallmark of these tumors. Efforts to inhibit various protein kinases in this pathway have led to the development of MEK inhibitors. Selumetinib is one such drug, functioning as an oral, selective non-ATP-competitive MEK1/2 inhibitor.Areas covered: In this article, the authors discuss the underlying biology of MEK inhibition and its rationale in cancer treatment. Furthermore, the authors summarize the clinical development of selumetinib in various tumor types, from initial Phase I studies to randomized Phase II studies, both as monotherapy or in combination with other chemotherapeutics.Expert opinion: Given the frequency of activated MAPK signaling in multiple tumor types, the potent MEK inhibitor selumetinib had strong preclinical and early clinical rationale, particularly in those tumors harboring KRAS or BRAF mutations. While efficacy signals have been seen in various tumor types treated with selumetinib, better biomarkers are needed to select patients most likely to respond favorably to this agent. Furthermore, combinatorial therapy with selumetinib and other targeted agents can likely be optimized to maximize the antitumor effect of inhibiting RAS/MAPK signaling.

KW - ARRY-142886

KW - AZD6244

KW - Extracellular signal-related kinase

KW - MAPK

KW - Mitogen-Activated protein kinase

KW - Selumetinib

UR - http://www.scopus.com/inward/record.url?scp=84916620321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916620321&partnerID=8YFLogxK

U2 - 10.1517/13543784.2015.982275

DO - 10.1517/13543784.2015.982275

M3 - Article

AN - SCOPUS:84916620321

VL - 24

SP - 111

EP - 123

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 1

ER -